• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Infect Dis. Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

tetano

Editor, Senior Moderator
Clin Infect Dis. 2020 Apr 27. pii: ciaa489. doi: 10.1093/cid/ciaa489. [Epub ahead of print]
Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).


Qu J[SUP]1[/SUP], Wu C[SUP]1[/SUP], Li X[SUP]1[/SUP], Zhang G[SUP]1[/SUP], Jiang Z[SUP]1[/SUP], Li X[SUP]2[/SUP], Zhu Q[SUP]1[/SUP], Liu L[SUP]3[/SUP].

Author information




Abstract

We profiled the serological responses to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein and spike (S) glycoprotein. The majority of the patients developed robust antibody responses between 17 and 23 days after illness onset. Delayed, but stronger antibody responses were observed in critical patients.
? The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.



KEYWORDS:

COVID-19; IgG; IgM; SARS-CoV-2; Serologic Responses


PMID:32337590DOI:10.1093/cid/ciaa489
 
Back
Top